151 related articles for article (PubMed ID: 1452117)
1. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
Vicari AM; Viganó D'Angelo S; Testa S; Comi G; Galardi G; Orsi E; D'Angelo A
Horm Metab Res; 1992 Nov; 24(11):516-9. PubMed ID: 1452117
[TBL] [Abstract][Full Text] [Related]
2. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
[TBL] [Abstract][Full Text] [Related]
3. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
4. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
Skrha J; Hodinár A; Kvasnicka J; Hilgertová J
Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of spontaneous fibrinolytic activity in diabetic retinopathy.
Ostermann H; Tschöpe D; Greber W; Meyer-Rüsenberg HW; van de Loo J
Thromb Haemost; 1992 Oct; 68(4):400-3. PubMed ID: 1448770
[TBL] [Abstract][Full Text] [Related]
6. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
7. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
Ceriello A; Quatraro A; Marchi E; Barbanti M; Giugliano D
Diabete Metab; 1993; 19(2):225-9. PubMed ID: 8339853
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Mansfield MW; Catto AJ; Carter AM; Grant PJ
Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
[TBL] [Abstract][Full Text] [Related]
9. Altered endothelial function following the Fontan procedure.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
[TBL] [Abstract][Full Text] [Related]
10. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
11. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
12. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
Stegnar M; Mavri A
Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
[TBL] [Abstract][Full Text] [Related]
14. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
[TBL] [Abstract][Full Text] [Related]
15. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
17. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
20. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
